Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros








Base de dados
Intervalo de ano de publicação
1.
Iran J Pharm Res ; 21(1): e126922, 2022 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-36060920

RESUMO

Background: As polypharmacy has some medically negative impacts, it has become a challenging issue for public health and affected people. Therefore, we decided to investigate the prevalence of polypharmacy and its predicting risk factors in the Azar cohort population. Methods: In this cross-sectional population-based cohort study, the prevalence of polypharmacy was evaluated in 15,001 subjects who participated in the Azar cohort study. We measured demographic characteristics (age, gender, socioeconomic status, smoking status, marital status, and education level), physical activity level, body mass index (BMI), blood pressure, multimorbidity (coexistence of two or more chronic diseases (CDs)), and polypharmacy status (a daily intake of five or more medicines for a minimum of 90 days). Results: Based on our results, 9.51% of the population had polypharmacy. The five most prescribed medications were drugs acting on the cardiovascular system (19.9%), central nervous system (16.7%), endocrine system (13.3%), NSAIDs (11.5%), and drugs used for musculoskeletal and joint diseases (11.4%). Being female, illiterate, and having the lowest tertile of physical activity level significantly increased the risk of polypharmacy. The risk of polypharmacy was 49.36 times higher in patients with four or more CDs than in those without. Conclusions: Our study emphasized the importance of routine monitoring to evaluate polypharmacy among those aged 35 to 59 and the elderly. Physicians should carefully assess drug suitability, especially in multimorbid and obese patients, to prevent excessive polypharmacy and its potentially negative impacts.

2.
Mikrochim Acta ; 186(3): 194, 2019 02 18.
Artigo em Inglês | MEDLINE | ID: mdl-30778721

RESUMO

A fluorescent nanoprobe is designed for the determination of carbamazepine (CBZ) in exhaled breath condensate (EBC) of patients receiving CBZ. The probe consists of copper nanoclusters (Cu NCs) coated with cetyl trimethylammonium bromide. The interaction of probe with CBZ results in blocking non-radiative e-/h+ recombination defect sites on the surface of Cu NCs and consequently enhancing the blue-green fluorescence of Cu NCs (excitation/emission wavelengths: 290/480 nm). The experimental conditions were optimized using a response surface methodology (central composite design). Under the optimized conditions, the calibration plot is linear in the 0.2 to 20 µg mL-1 CBZ concentration range and the detection limit is as low as 0.08 µg mL-1. The intra-day and inter-day relative standard deviations for six replicated measurements of 10 µg mL-1 CBZ are 3.9% and 4.8%, respectively. The method was applied for the determination of CBZ level in EBC of patients receiving CBZ. The accuracy of the method was confirmed by HPLC-UV analysis as a reference method. Graphical abstract Graphical abstract contains poor quality and small text inside the artwork. Please do not re-use the file that we have rejected or attempt to increase its resolution and re-save. It is originally poor, therefore, increasing the resolution will not solve the quality problem. We suggest that you provide us the original format. We prefer replacement figures containing vector/editable objects rather than embedded images. Preferred file formats are eps, ai, tiff and pdf. "Figures 1 contains poor quality of text inside the artwork. Please do not re-use the file that we have rejected or attempt to increase its resolution and re-save. It is originally poor, therefore, increasing the resolution will not solve the quality problem. We suggest that you provide us the original format. We prefer replacement figures containing vector/editable objects rather than embedded images. Preferred file formats are eps, ai, tiff and pdf.A new PDF format of Graphical Abstract was provided in attachment section. Schematic presentation of cetyl trimethylammonium bromide coated copper nanocluster's response to carbamazepine.


Assuntos
Carbamazepina/análise , Cetrimônio/química , Cobre/química , Corantes Fluorescentes/química , Nanopartículas Metálicas/química , Técnicas Biossensoriais , Testes Respiratórios/métodos , Cromatografia Líquida de Alta Pressão , Humanos , Limite de Detecção , Tamanho da Partícula , Espectrometria de Fluorescência , Propriedades de Superfície
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA